IL1B and cancer: Currently, several agents are available to inhibit IL-1, which include IL-1Ra (anakinra), IL-1β specific antibodies (canakinumab), as well as inflammasome inhibitors.179–181 Notably, multiple cancer therapeutic agents such as chemotherapeutic drugs, MAPK inhibitors, and BRAF V600E inhibitor (BRAFi) have been reported to either increase the expression of IL-1β or activate inflammasomes in myeloid cells,182,183 causing unwanted side effects.